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Background
To cover the genetic diversity of HIV-1 among Asian coun-
tries, three mosaic HIV-1 DNA vaccines encompassing the
gag gene derived from HIV-1 CRF01_AE and Asian HIV-1
subtype B were constructed and tested for immunogenic-
ity in Balb/c mice.
Methods
Full-length gag sequences of 1.5 kb derived from 156
CRF01_AE and 72 Asian HIV-1 subtype B were computer-
ized to generate 3 representative mosaic Asian HIV-1 gag
genes. The mosaic gag  genes were RNA-optimized and
cloned into pCMVkan expression vector. Mice were
immunized by intradermal (ID) and needle-free injector
(NF) using 100 and 50 μg, respectively, of the 3 mosaic-
gag mixtures. The vaccinations were performed on days 0,
14 and 28. An additional group received 5-million pfu
vaccinia-AE boost on day 42. Mice were sacrificed on day
35 (DNA alone) and day 49 (DNA prime/vaccinia boost)
and the immunogenicity was assessed by anti-p24 anti-
body and IFN-gamma ELISpot assays. Both HIV-1 AE- and
B-peptide pools were used separately to stimulate spleno-
cytes.
Results
All mice showed anti-p24 antibody responses of at least
1:10,000. For ELISpot assay, with the AE-peptide pool
stimulation, the responses (median spots (range)) were
430 (291–643) and 953 (641–1206) for ID and NF
groups, respectively. Whereas with the B-peptide pool
stimulation, the responses were 560 (411–776) and 1151
(711–1352) for the ID and NF groups, respectively. The
NF group showed statistically higher cellular immune
responses testing either peptide pools (p = 0.0043 for AE
& B, Mann-Whitney test). The prime/boost strategy using
AE vaccinia virus gave much better responses of
1756(1062–2293) when stimulated with the AE-pool (p
= 0.0087) but no increase in B-peptide responses (930
spots (679–1270)).
Conclusion
Our results suggest that the mosaic Asian HIV-1 DNA vac-
cine was immunogenic and could induce both humoral-
and cell-mediated immune responses with appropriate
immunization modification, i.e., using NF and prime/
boost strategies.
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